Concepedia

Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity

Ulrike Garske‐Román, Mattias Sandström, Katarzyna Fröss Baron, Lars Lundin, Per Hellman, Staffan Welin, Silvia Johansson, Tanweera Khan, Hans Lundqvist, Barbro Eriksson,

European Journal of Nuclear Medicine and Molecular Imaging · 2018 · 249 citations · 37 references

DOIFull text

Open access

Concepts

References

37

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

, , +14

Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors

Jonathan Strosberg, Ghassan El‐Haddad, Edward M. Wolin et al. · New England Journal of Medicine · 2017 · 3.2K citations · Full text

, , +17

Treatment With the Radiolabeled Somatostatin Analog [ <sup>177</sup> Lu-DOTA <sup>0</sup> ,Tyr <sup>3</sup> ]Octreotate: Toxicity, Efficacy, and Survival

Dik J. Kwekkeboom, Wouter W. de Herder, Boen L.R. Kam et al. · Journal of Clinical Oncology · 2008 · 1.4K citations · Full text

, , +17

Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study

Staffan Welin, Seppo W. Langer, Lene Weber Vestermark et al. · Annals of Oncology · 2012 · 1K citations

, , +12

Radiolabeled Somatostatin Analog [<sup>177</sup>Lu-DOTA<sup>0</sup>,Tyr<sup>3</sup>]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors

Dik J. Kwekkeboom, Jaap J.M. Teunissen, Willem H. Bakker et al. · Journal of Clinical Oncology · 2005 · 659 citations · Full text

, , +15